Latest news with #VLA15
Yahoo
26-05-2025
- Business
- Yahoo
Valneva to Participate at U.S. and European Investor Conferences in June
Saint-Herblain (France), May 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and hold investor meetings at several upcoming investor conferences in the United States and Europe in June 2025. Key topics for discussion include Valneva's commercial stage vaccines and its differentiated portfolio of vaccine candidates, including VLA15, the world's leading Lyme disease vaccine candidate. VLA15 is partnered with Pfizer and currently being evaluated in a pivotal Phase 3 trial for which the Company expects first data at the end of 2025. Institutional investors who would like to meet 1on1 with management at any of the below conferences are asked to submit a request to their representative at the respective bank. Jefferies Global Healthcare Conference Format Fireside chat and investor meetingsDate/ time June 5, 2025, 11:40am ETWebcast Link. A replay of the webcast will also be available in the 'Investor' section of the Valneva New York Goldman Sachs 46th Annual Global Healthcare Conference: Format Fireside chat and investor meetingsDate/ time June 9, 2025, 1:20pm ET Location Miami, FL Oddo BHF Nextcap Forum: Format Investor meetings onlyDate/ time June 12, 2025Location Virtual BNP Paribas SMID Cap Conference: Format Investor meetings onlyDate/ time June 18, 2025Location Paris, France About Valneva SE We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against the Zika virus and other global public health threats. More information is available at Valneva Investor and Media ContactsLaetitia Bachelot-FontaineVP, Global Communications and European Investor RelationsM +33 (0)6 4516 Joshua Drumm, Global Investor Relations M +001 917 815 Forward-Looking StatementsThis press release contains certain forward-looking statements relating to the business of Valneva, including with respect to use and regulatory review of existing products. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be sustained in the future. In some cases, you can identify forward-looking statements by words such as 'could,' 'should,' 'may,' 'expects,' 'anticipates,' 'believes,' 'intends,' 'estimates,' 'aims,' 'targets,' or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties and delays involved in the development and manufacture of vaccines, unexpected clinical trial results or new adverse events, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, and the ability to obtain or maintain patent or other proprietary intellectual property protection. Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will in fact be realized. Valneva is providing this information as of the date of this press release and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Attachment 2025_05_26_VLA_June_2025_Conferences_PR_EN_Final
Yahoo
01-04-2025
- Business
- Yahoo
Is Valneva (VALN) the Best Performing NASDAQ Stock So Far in 2025?
We recently published a list of . In this article, we are going to take a look at where Valneva (NASDAQ:VALN) stands against other best performing NASDAQ stocks so far in 2025. On March 29, T. Rowe Price portfolio manager Tony Wang appeared on CNBC's 'Closing Bell Overtime' to discuss the current volatility in the tech sector, especially the NASDAQ. The NASDAQ underperformed throughout March and registered the largest decline since June 2022. But the question that now arises is whether this decline and volatility present a buying opportunity or not. Wang leans towards less caution and more confidence in this potential bull market. To support his sentiment, he cited that growth and momentum have both been high in recent years. Tech stocks in particular have seen substantial growth in the past 2 year. He thinks that valuations could further improve, given that the sector recent strong years came from AI infrastructure build out. Wang also acknowledged that companies are naturally questioning whether current spending levels in the sector are sustainable or not. But he reiterated that compute will retain its value, despite concerns about whether it has a cyclical position or not. He also noted that deep tech could potentially lower inferencing costs and expand market access for companies that enter with limited capital. Like any other sector, cost reduction is an ideal long-term outcome for the tech industry as well. We used the Finviz stock screener to compile a list of all the best-performing NASDAQ stocks. We then picked the 11 NASDAQ stocks with the highest year-to-date gains, as of March 31. The stocks are ranked in ascending order of their year-to-date performance. We have also added the hedge fund sentiment for each stock which was sourced from Insider Monkey's database. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here). A scientist examining a petri dish filled with virus cultures. Number of Hedge Fund Holders: 2 Average Upside Potential as of March 31: 53.48% Valneva (NASDAQ:VALN) develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It sells its products globally and has collaborations with Pfizer Inc. to co-develop and commercialize its Lyme disease vaccine. It also collaborates with Instituto Butantan to develop, manufacture, and market single-shot chikungunya vaccine. The partnership with Pfizer Inc. is projected the exceed $1 billion at its peak for the Lyme disease vaccine market. Positive data, regulatory approvals, and the commercialization of VLA15, which is the candidate under this partnership, will result in significant payments and royalties. This will sustain the company's profitability from late 2027 onwards. This vaccine addresses unmet medical needs with no present preventative measures, such as Lyme disease in humans, as mentioned earlier. There are ~500,000 patients for this disease in the US, with ~130,000 cases in Europe. VALOR is the Phase 3 study for VLA15 and is progressing positively with the first data readout expected by the end of 2025. The study involves ~9,000 participants aged 5 or older. If the study is successful, regulatory filings are expected for 2026 with potential approvals in 2027. Overall, VALN ranks 11th on our list of best performing NASDAQ stocks so far in 2025. While we acknowledge the growth potential of VALN, our conviction lies in the belief that AI stocks hold great promise for delivering high returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than VALN but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
